תרופות נוגדות קרישה וטסיות בחולים העוברים צנתור כלילי התערבותי פרופ' אלי לב מנהל יחידת הצנתורים בי"ח השרון, מרכז רפואי רבין.

Slides:



Advertisements
Similar presentations
August 30, 2009 at CET. Ticagrelor compared with clopidogrel in patients with acute coronary syndromes – the PLATO trial.
Advertisements

Invasive Ticagrelor compared with clopidogrel in patients with acute coronary syndromes – the PLATelet Inhibition and patient Outcomes trial Outcomes in.
Progress in Oral Anti- Platelet Therapy Rabih R. Azar, MD, MSc, FACC Division of Cardiology Hotel Dieu de France Hospital 1.
Stone p2203/Abstract/ Conclusions
Anti thrombotics in STEMI Journal review Dr Nithin P G.
Canadian Diabetes Association Clinical Practice Guidelines Acute Coronary Syndromes and Diabetes Chapter 26 Jean-Claude Tardif, Phillipe L. L’Allier, David.
Oral Antiplatelet Agents: A Cornerstone of Therapy for Atherothrombotic Disease Aspirin and clopidogrel: - Reduce the risks of myocardial infarction, ischemic.
Vascular Pharmacology
Prasugrel vs ticagrelor in acute coronary syndromes
Ticagrelor compared with clopidogrel in patients with acute coronary syndromes – the PLAT elet Inhibition and patient O utcomes trial Outcomes in patients.
Khawar Kazmi. Thrombosis LipidsInflammation Thrombus Platelets and thrombin Quiescent Plaque Plaque rupture PATHOGENESIS ACUTE CORONARY SYNDROME.
Giuseppe Biondi-Zoccai Division of Cardiology, University of Turin, Turin, Italy.
Antiplatelet Drugs (Anti-thrombotics)
TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel TRITON-TIMI 38 TRITON-TIMI 38 Elliott M. Antman, MD.
ACS is a major public health challenge In the US:  Over 1.5 million people experience ACS annually 1 In the EU:  ACS is the most common cause of death,
Clopidogrel in ACS: Overview Investigator, TIMI Study Group Associate Physician, Cardiovascular Division, BWH Assistant Professor of Medicine, Harvard.
The Landscape of Oral Antiplatelet Agents 2009 George D. Dangas, MD, PhD, FSCAI, FACC Associate Professor of Medicine Columbia University Medical Center.
Antiplatelet Drugs - Principles Benedict R. Lucchesi, M.D., Ph.D. Department of Pharmacology University of Michigan Medical School.
Ticlopidine (Ticlid™) and Clopidogrel (Plavix™) Benedict R. Lucchesi, M.D., Ph.D. Department of Pharmacology University of Michigan Medical School.
C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind.
Intravenous GP IIb/IIIa Inhibitors Abciximab (c7E3 Fab, ReoPro) = Human- murine chimeric monoclonal Fab antibody fragment Eptifibatide (Integrilin) =
A Prospective, Randomized Comparison of Bivalirudin vs. Heparin Plus Glycoprotein IIb/IIIa Inhibitors During Primary Angioplasty in Acute Myocardial Infarction.
Rob Storey Reader and Honorary Consultant in Cardiology, University of Sheffield The changing world of adjunctive pharmacology.
Robert F. Storey Senior Lecturer and Honorary Consultant in Cardiology, University of Sheffield, Sheffield, UK Stent thrombosis Future directions.
Stents Are Not Enough: Recent Clopidogrel Data Rob Henderson Nottingham City Hospital Rob Henderson Nottingham City Hospital.
Applications of bivalirudin in interventional cardiology
Evolution of pharmaceutical antithrombotic therapy in CVD Dr Rob Butler Dept of Cardiology University Hospital of North Staffordshire Drug It!
Dr Robert F. Storey Senior Lecturer and Honorary Consultant in Cardiology, University of Sheffield, Sheffield UK Managing bleeding post PCI.
Aspirin Resistance: Significance, Detection and Clinical Management of This Real Phenomenon Webcast May 10 th, 2004 Sponsored by.
CABG Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO trial Claes.
Karlis TRUSINSKIS Interventional Cardiologist Pauls Stradins Clinical University Hospital Riga, LATVIA ANTIAGREGANTS IN ACUTE CORONARY SYNDROME.
ANTIPLATELET DRUGS.
What’s New in Acute Coronary Syndromes? Claudia Bucci BScPhm, PharmD Clinical Coordinator, Cardiovascular Diseases Sunnybrook Health Sciences Centre 13.
John H. Alexander, MD, MHS Associate Professor of Medicine Director, Cardiovascular Research Duke Clinical Research Institute Duke Medicine Update on antithrombotics.
Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis HORIZONS AMI Dangas G, et al.
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
Glycoprotein IIb/IIIa inhibitors and bivalirudin: under utilised? Azfar Zaman Freeman Hospital Newcastle-upon-Tyne.
STEMI < 6 h Lytic eligible Lytic choice by MD (TNK, tPA, rPA, SK) ENOX < 75 y: 30 mg IV bolus SC 1.0 mg / kg q 12 h (Hosp DC) ≥ 75 y: No bolus SC 0.75.
Do Tirofiban And ReoPro Give Similar Efficacy Outcomes Trial Presented at AHA Scientific Sessions Nov. 15, 2000.
The Additive Value of Tirofiban Administered With the High-Dose Bolus in the Prevention of Ischemic Complications During High-Risk Coronary Angioplasty.
ANTIPLATELET DRUGS Learning objectives By the end of this lecture, students should be able to: - describe different classes of anti-platelet drugs and.
ANTIPLATELETES AGENTS BY :DR. ISRAA OMAR. The role of platelets Platelets play a critical role in thromboembolic disease like ischemic heart disease and.
ANTIPLATELETES AGENTS
New Horizons for Patients with ST-Elevation Myocardial Infarction Gregg W. Stone MD Columbia University Medical Center Cardiovascular Research Foundation.
Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine Update on Novel Antiplatelet Agents Under.
Pocket Guide to Anticoagulation in AF & Dual Antiplatelet Therapy in ACS Rumi Jaumdally 2015 This brief presentation will summarise the recently published.
Medical management after PCI Ma Hong 1 st affiliated hospital of Sun Yat-sen University.
1 Advanced Angioplasty London, England 27 January, 2006 Jörg Michael Rustige,MD Medical Director Lilly Critical Care Europe, Geneva.
Dr Jonathan Day Senior Director Global Medical The Medicines Company Bivalirudin For patients with STEMI undergoing primary PCI.
Dr Jonathan Day Senior Director Global Medical The Medicines Company Bivalirudin Advancing Anticoagulation in ACS.
David J. Moliterno, MD, MPH Chief, Cardiovascular Medicine Professor & Vice-Chair of Medicine University of Kentucky Co-Director - Gill Heart Institute.
VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Bivalirudin: Myths vs Reality? Dr Reman McDonagh Nycomed UK Ltd Conflict of Interest: Senior Manager working for Nycomed UK Ltd.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
Prof. Abdulrahman Almotrefi
Coagulation and fibrinolysis
Duration Safety and Efficacy of Bivalirudin in patients undergoing PCI: The impact of duration of infusion in ACUITY trial Dr. David Cox Lehigh Valley.
수요저널 우종신. ACC/AHA Guideline Focused Update 2011 Class I 1. After PCI, use of aspirin should be continued indefinitely. (Level of Evidence.
1 Do Tirofiban And ReoPro Give Similar Efficacy Outcomes Trial N Engl J Med 2001;344:
Adjunctive Antithrombotic for PCI Theodore A Bass, MD FSCAI President SCAI Professor of Medicine, University of Florida Medical Director UF Shands CV Center,Jacksonville.
The American College of Cardiology Presented by Dr. Adnan Kastrati
Should We Preload STEMI Patients with Antiplatelet Therapy?
For the HORIZONS-AMI Investigators
Antiplatelet Therapy For STEMI: The Case for Cangrelor
For the HORIZONS-AMI Investigators
For the HORIZONS-AMI Investigators
August 30, 2009 at CET. Ticagrelor compared with clopidogrel in patients with acute coronary syndromes – the PLATO trial.
Erasmus MC, Thoraxcenter
What oral antiplatelet therapy would you choose?
Prof. Abdulrahman Almotrefi
Presentation transcript:

תרופות נוגדות קרישה וטסיות בחולים העוברים צנתור כלילי התערבותי פרופ' אלי לב מנהל יחידת הצנתורים בי"ח השרון, מרכז רפואי רבין

3 Major systems involved in thrombosis and hemostasis Vessel wall –Endothelium Platelets Coagulation cascade

Anti-platelet and Anti-coagulant Properties of the Endothelium –Covers highly thrombogenic basement membrane (collagen, TF). Uninjured endothelium does not bind platelets –NO from uninjured endothelium inhibit platelet aggregation and adhesion, PGI2 (prostacyclin) inhibits platelet aggregation –TFPI – tissue factor pathway inhibitor – released from endothelial cells –Endothelial cells produce t- PA which activates fibrinolysis via plasminogen to plasmin

Platelet Adhesion Platelets are the first cells to adhere to injured vascular wall (subendothelium) Adhesion is mediated by vWF Binding occurs only under high shear stress conditions !

Platelet Activation (Plasma) (released from activated cells) (ECM)

Platelet Aggregation 1. Kuwahara M et al. Arterioscler Thromb Vasc Biol 2002; 22: 329–34. FIRM, BUT REVERSIBLE ADHESION IRREVERSIBLE ADHESION Scanning electron micrograph of discoid, dormant platelets Activated, aggregating platelets illustrating fibrin strands Flowing disc-shaped platelet Rolling ball-shaped platelet Hemisphere-shaped platelet Spreading platelet

3 Major systems involved Vessel wall –Endothelium Platelets Coagulation cascade

FibrinogenFibrin Thrombin Prothrombin Xa Va VIIa TF Extrinsic Pathway IXa VIIIa XIa XIIa Intrinsic pathway XIIIa Soft clot Fibrin Hard clot “Classic Coagulation Cascade”

Rosenberg et al NEJM major Anti-thrombotic Pathways (TFPI, Prot C/S, ATIII, Plasmin) Localization to sites of vascular injury. Protease complexes assemble on PL membranes of activated platelets, endothelial cells and monocytes. (The coagulation cascade occurs very slowly in fluid phase plasma and with resting cells)

From “Classic” to Current View

Current View of the Coagulation System Initiation by vessel wall injury which exposes blood to cells with TF on their surface  TF/FVIIa activates FX  Xa + Va cleaves II  small amounts of IIa (thrombin) Minute amounts of thrombin produced initially than lead to a marked increase in activation of FXI, FIX, FVIII, FV and marked generation of thrombin. Priming invloves adherence and activation of platelets.The small amounts of initial thrombin activates platelets  release of FV + PL surface for protease activation Propagation – an explosive increase in thrombin generation mediated by the classic “intrinsic system”  FXI, FIX  Fxa/VIIIa/Va on activated platelets  IIa + fibrin formation Schneider D et al, Circulation 2007

“The Great Balance” Thrombotic Complications Bleeding Complications

Mortality (%) Days from Randomization year Estimate Major Bleed only (without MI) (N=551)12.5% 28.9%Both MI and Major Bleed (N=94) 3.4%No MI or Major Bleed (N=12,557) MI only (without Major Bleed) (N=611)8.6% Significance of bleeding: Impact of MI and Major Bleeding (non-CABG) in first 30 Days on Risk of Death Over 1 Year 28.9% 12.5% 8.6% 3.4% ACUITY – 1 year

Courtesy of Dr S. Steinhubl, U. Kentucky

Placebo alone: 568/4300 (13.2%) Aspirin alone: 461/4295 (10.7%) Streptokinase alone: 448/4300 (10.4%) Streptokinase plus aspirin: 343/4292 (8.0%) Cumulative Number of Vascular Deaths Days From Randomization Aspirin in Acute Myocardial Infarction: ISIS-2 (Lancet 1988;2:349-60)

Aspirin in the Treatment of ACS Wallentin LC, et al. JACC 1991;18: Months Probability of Death or MI Placebo Aspirin 75 mg Risk ratio % CL

Comparison of ASA Doses on Vascular Events in High-Risk Patients *Odds reduction. Treatment effect P< ASA, acetylsalicylic acid. Adapted with permission from BMJ Publishing Group. Antithrombotic Trialists’ Collaboration. BMJ. 2002;324: mg mg mg12 32 <75 mg 3 13 Any aspirin65 23 Antiplatelet BetterAntiplatelet Worse Aspirin DoseNo. of Trials (%) Odds Ratio 0 OR*

Clopidogrel

Efficacy of anti-platelet agents in reducing coronary events after stenting Cumulative event rate (%)

CURE TRIAL – ACS pts 20 % reduction in primary endpoint (N Engl J Med. 2001;345: )

PCI-CURE TRIAL – ACS pts Pretreatment with clopidogrel vs. no pretreatment Reduction in CV death, MI or urgent TVR CURE Investigatots, Lancet :

Distribution of Response to Clopidogrel (544 patients, platelet aggregation) Change in Aggregation to 5µM ADP Number of patients <= -20[-10,0][11,20][31,40][51,60][71,80][91,100] Serebrauny V et al. JACC 2004

PLATELET FUNCTION ASSAYS REVEALE EXTREME INTER-PATIENT VARIABILITY* Courtesy of Aradi, Collet. * After 600 mg clopidogrel loading dose, in patients with stable angina undergoing PCI

ADAPT-DES: DEFINITE / PROBABLE 30 days Stone et al, Lancet 2013

Low response to clopidogrel in patients with ACS: RECLOSE-2 P=0.003 P< patients with ACS High on treatment platelet reactivity (low response) determined by LTA in response to ADP 14% of pts had HTPR Primary endpoint = cardiac death, MI, urgent revasc. or stroke Antoniucci et al, JAMA 2011

Prasugrel: Active Metabolite Formation Faster Onset of IPA HOOC * HS N N O O F F N N S S O O C C H H 3 3 C C O O F F PrasugrelPrasugrel Pro-drugPro-drug Hepatic Metabolism Cytochrome P450 Active Metabolite N N S S O O F F O O HOOC * HS N N O O Cl OCH 3 Sem Vasc Med 3:113, 2003 Pre-hepatic metabolism - Hydrolysis Esterases in blood O O 85% Inactive Metabolites (hydrolysis) O O N N S S O O Cl O O CH 3 CC N N S S O O Cl O O CH 3 CC N N S S O O Cl O O CH 3 CC ClopidogrelClopidogrel

* * * * * * * * Prasugrel 10 mg MD vs. Clopidogrel 75 mg MD: Higher IPA During Maintenance Dosing mean ± SEM 20 μM ADP mean ± SEM 20 μM ADP Inhibition of Platelet Aggregation (%) Loading Dose Maintenance Doses Time HoursDays Clop 300 mg Clop 75 mg † † ! ! † § P<0.001 vs. Clop 300 mg or 600 mg LD * P<0.001 vs. Clop 300 mg or 600 mg LD P<0.001 vs. Clop 300 † P<0.001 vs. Clop 300 P<0.05 vs. Clop 300 P<0.05 vs Clop 300/75 ! P<0.05 vs. Clop 300 § P<0.05 vs Clop 300/75 Clop 600 mg Clop 75 mg * * * * * Pras 60 mg Pras 10 mg Payne CD et al. Presented at TCT 2006.

CABG=Coronary Artery Bypass Graft surgery; CV=Cardiovascular; MI=Myocardial Infarction; TIMI=Thrombolysis In Myocardial Infarction Prasugrel Clopidogrel TRITON-TIMI 38: Rates of Key Study End Points (13,500 pts with ACS) Wiviott SD et al. New Engl J Med 2007;357: Days After Randomization End Point (%) (111) 2.4 (146) Non-CABG TIMI Major Bleeds CV Death, MI, Stroke P=0.03 P<0.001 ↓138 events ↑ 35 events 12.1 (781) 9.9 (643) Prasugrel Clopidogrel

TRITON-TIMI 38: ARC Definite/Probable Stent Thrombosis: ARC=Academic Research Consortium; ARR=Absolute Risk Reduction; HR=Hazard Ratio; NNT=Number Needed to Treat; PCI=Percutaneous Coronary Intervention; RRR=Relative Risk Reduction Wiviott SD et al. Lancet 2008;371: HR 0.48 ( ) P< RRR 52% ARR 1.22% Prasugrel Clopidogrel Days Stent Thrombosis (%) Any Stent at Index PCI n=12, NNT=77

ACS=Acute Coronary Syndrome; CABG=Coronary Artery Bypass Graft surgery; HR=Hazard Ratio; TIMI=Thrombolysis In Myocardial Infarction P=0.002 Odds Ratio 4.73 P<0.001 TIMI Major or Minor CABG-related TIMI Major Bleeding Requiring Transfusion P<0.001 At risk 6/189 At risk 24/179 (n=6,716) (n=6,741) End Point (%) 3.2% 13.4% n=244 n=182 n=231 n= % 5.0% 3.0% 4.0% Wiviott SD et al. New Engl J Med 2007;357: TRITON-TIMI 38: TIMI Bleeds at 15 mo (all ACS) TIMI major bleeding: 1.8% vs. 2.4%, (P=0.03), Pras vs. Clop

Bleeding Risk Subgroups Therapeutic Considerations Significant Net Clinical Benefit with Prasugrel 80% Reduced MD Guided by PK Age > 75 or Wt < 60 kg 16% Avoid Prasugrel Prior CVA/TIA 4% TRITON-TIMI 38, NEJM 2007

TRITON-TIMI 38: Diabetic Subgroup Analysis (n=3,146) CABG=Coronary Artery Bypass Graft surgery; CV=Cardiovascular; HR=Hazard Ratio; MI=Myocardial Infarction; NNT= Number Needed to Treat; TIMI=Thrombolysis In Myocardial Infarction Adapted from Antman EM et al. American Heart Association Scientific Sessions; 2007, Nov 4-7; Orlando, FL HR 0.70 P<0.001 Days End Point (%) CV Death, MI, Stroke NNT= Non-CABG TIMI Major Bleeds Prasugrel Clopidogrel

TRITON-TIMI 38: STEMI Subgroup Analysis (n=3,534) P=0.05 P=0.045 P=0.01 P=0.4

Ticagrelor (AZD 6140): an oral reversible P2Y 12 antagonist Ticagrelor is a cyclo-pentyl- triazolo-pyrimidine (CPTP) Direct acting – Not a prodrug; does not require metabolic activation – Rapid onset of inhibitory effect on the P2Y 12 receptor – Greater and more consistent inhibition of platelet aggregation versus clopidogrel Reversibly bound – Degree of inhibition reflects plasma concentration – Faster offset of effect than clopidogrel – Functional recovery of all circulating platelets

Last Maintenance Dose Loading Dose Time (hours) Onset Maintenance Offset IPA % Ticagrelor (n=54) Clopidogrel (n=50) Placebo (n=12) weeks * * * * * * * * * ‡ † † Onset / Offset Study, IPA to 5uM ADP Gurbel PA et al. Circulation 2009

PLATO study primary efficacy event - CV death, MI or stroke (18,600 pts with ACS) No. at risk Clopidogrel Ticagrelor 9,291 9,333 8,521 8,628 8,362 8,460 8,124 Days after randomisation 6,743 5,096 5,161 4,047 4, Cumulative incidence (%) ,219 HR 0.84 (95% CI 0.77–0.92), p= Clopidogrel Ticagrelor K-M = Kaplan-Meier; HR = hazard ratio; CI = confidence interval

K-M estimates of time to secondary efficacy endpoints No. at risk Clopidogrel Ticagrelor 9,291 9,333 8,560 8,678 8,405 8,520 8,177 Days after randomisation 6,703 6,796 5,136 5,210 4,109 4, Cumulative incidence (%) Clopidogrel Ticagrelor ,279 HR 0.84 (95% CI 0.75–0.95), p= Clopidogrel Ticagrelor HR 0.79 (95% CI 0.69–0.91), p= ,291 9,333 8,865 8,294 8,780 8,822 8,589 Days after randomisation ,441 5,482 4,364 4,4198,626 Myocardial infarction Cardiovascular death !!! Cumulative incidence (%)

Stent thrombosis Evaluated in patients with any stent during the study Wallentin et al, N Engl J Med 2009 P=0.01 P=0.02 %

Major bleeding – primary safety event No. at risk Clopidogrel Ticagrelor 9,186 9,235 7,305 7,246 6,930 6,826 6,670 Days from first IP dose 5,209 5,129 3,841 3,783 3,479 3, Clopidogrel Ticagrelor ,545 HR 1.04 (95% CI 0.95–1.13), p=0.434 K-M estimated rate (% per year)

Non-CABG and CABG-related major bleeding p=0.026 p=0.025 NS 9 K-M estimated rate (% per year) Non-CABG PLATO major bleeding Non-CABG TIMI major bleeding CABG PLATO major bleeding CABG TIMI major bleeding Ticagrelor Clopidogrel

Dyspnoea with Ticagrelor All patients Ticagrelor(n=9,235)Clopidogrel(n=9,186) p value * Dyspnoea, % Any Any Requiring discontinuation of study Rx Requiring discontinuation of study Rx <0.001<0.001 “Ticagrelor-related dyspnoea is usually mild or moderate in intensity, self- limiting and does not appear to be associated with differences in any efficacy or safety outcomes with ticagrelor compared with clopidogrel therapy in ACS pts.” Storey et al, Eur Heart J 2011

PLATO STEMI - Primary endpoint: CV death, MI or stroke Months HR: 0.85 (95% CI = 0.74–0.97), p=0.02 No. at risk Clopidogrel Ticagrelor 4,229 4,201 3,892 3,887 3,823 3,834 3,7303,022 3,011 2,333 2,297 1,868 1,8913, Clopidogrel Ticagrelor K-M estimated rate (% per year) Steg et al, Circulation 2010

PLATO STEMI - All cause mortality K-M estimated rate (% per year) 4,2014,0053,9623,8763,1502,4131,993 4,2294,0293,9893,9123,1952,4711,980 Months No. at risk Ticagrelor Clopidogrel Ticagrelor HR 0.82 (95% CI = 0.68–0.99), p=0.04

K-M estimated rate (% per year) Months No. at risk Ticagrelor Clopidogrel 4,1653,4313,2543,1372,4401,7861,640 4,1813,4303,2973,1592,4411,8041,635 Clopidogrel Ticagrelor PLATO STEMI - Primary safety event: major bleeding HR 0.96 (95% CI = 0.83–1.12), p=0.63 Steg et al, Circulation 2010

Platelet Activation (Plasma) (released from activated cells) (ECM)

GP IIb/IIIA Inhibitors Abciximab (ReoPro  ) – the first inhibitor developed and approved for clinical use. Chimeric monoclonal antibody – 7E3, the murine constant region was replaced by its human counterpart Eptifibatide (Integrilin  ) – synthetic cyclic hepta-peptide derived from a sequence found in the venom of the southeastern pygmy rattlesnake Tirofiban (Aggrastat  ) – synthetic small molecule with structure similar to that of the RGD sequence of the snake venom echistatin

Glycoprotein IIb/IIIa Receptor Antagonists 0.25 mcg/kg bolus followed by mcg/kg/min drip (max 10 mcg/min) for hours Synthetic non-peptide 0.4 mcg/kg/min for 30 minutes followed by 0.1 mcg/kg/min drip for hours Cyclic heptapeptide 180 mcg/kg bolus (x2) followed by 2.0 mcg/kg/min drip for hours Fab portion of chimeric monoclonal antibody 30 minutes 1.8 hours2.5 hours Not specific Highly specific AbciximabTirofibanEptifibatide Pharma Plasma ½ life Specificity Dose

ISAR-REACT 2 High-risk ACS Patients – 30 Days p=0.06 p=0.03 p=0.34p=0.64 JAMA 2006;295:

Abciximab in Primary PCI Meta-analysis 8 RCTs – 3,949 pts with AMI w/i 12  undergoing primary (7) or rescue (1) PCI rand to abciximab vs. placebo or control p=0.06 RR 0.71 [0.49,1.02] p=0.01 RR 0.72 [0.55,0.94] 6–12 months De Luca G et al. JAMA 2005;293:1759–1765

Updated meta-analysis of effect of GPIs on 30 day mortality in pts with STEMI De Luca rt al, EHJ 2009 Favors GPIsFavors Control

Updated meta-analysis of effect of GP IIb/IIIa inhibitors on 30 day re-MI De Luca rt al, EHJ 2009 Favors GPIsFavors control

Updated meta-analysis of effect of GP IIb/IIIa inhibitors on major bleeding De Luca rt al, EHJ 2009

C-terminal dodecapeptide (Exosite 1-binding portion) (Gly) 4 D-Phe-Pro-Arg-Pro (active-site-binding moiety) C-terminal dodecapeptide (Exosite 1-binding portion) (Gly) 4 D-Phe-Pro-Arg-Pro (active-site-binding portion) 2 1 Thrombin Bivalirudin Bivalirudin – a direct thrombin inhibitor - binds bivalently and with high affinity to thrombin’s active site A/BR//259.a.1

2 1 Thrombin Bivalirudin can displace fibrin bound to thrombin— Bivalirudin has high specificity for thrombin. Bivalirudin A/BR//260.a.1

Bivalirudin Bivalirudin is cleared from plasma by combination of renal mecahnisms and proteolytic cleavage Plasma half life = 25 minutes (norm renal funct) Mod. renal impairment, half life = 34 minutes (dose reduced) Almost immediate prolongation of ACT. aPTT Coagulation times return to normal after about 1 hour following drug d/c No HIT !!

HORIZONS 1-Year Major Adverse CV Events 3602 patients with STEMI undergoing 1 o PCI Number at risk Bivalirudin alone Heparin+GPIIb/IIIa ) Bivalirudin alone (n=1800) Heparin + GPIIb/IIIa (n=1802) MACE (%) Time in Months % 11.9% Diff [95%CI] = 0.0% [-2.1, 2.2] HR [95%CI] = 1.00 [0.83, 1.21] P=0.98 * *MACE = All cause death, reinfarction, ischemic TVR or stroke

9.2% 5.8% Diff [95%CI] = -3.4% [- 5.2, -1.7] 2 HR [95%CI] = 0.61 [0.48, 0.78] P< Year Major Bleeding (non-CABG) Bivalirudin alone (n=1800) Heparin + GPIIb/IIIa (n=1802)

1-Year Mortality: Cardiac and Non Cardiac Number at risk Bivalirudin alone Heparin+GPIIb/IIIa Bivalirudin alone (n=1800) Heparin + GPIIb/IIIa (n=1802) Cardiac Non Cardiac Mortality (%) Time in Months % 2.1% 1.3% 1.1% HR [95%CI] = 0.57 [0.38, 0.84] P= % 1.8% Δ = 1.1% P=0.03 Δ = 1.7%

NCDR PCI registry including >1,500,000 pts undergoing PCI in 955 US hospitals 23% of the patients treated with bivalirudin 50% elective, 36% urgent, 14% emergent PCI Bivalirudin associated with OR 0.67 ( ) for bleeding events !! (Bleeding defined as requiring blood transfusion, prolonged hospital stay, or ↓ 3 g/dL in Hg)

THANK YOU